Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Cemiplimab/PEG-Interferon-α Combination for Advanced Cutaneous Squamous Cell Carcinoma (aCSCC)

NCT05729139 is registered in ClinicalTrials.gov with Baptist Health South Florida as lead sponsor.

NCT NCT05729139
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05729139 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Cemiplimab/PEG-Interferon-α Combination for Advanced Cutaneous Squamous Cell Carcinoma (aCSCC)
Lead sponsor
Baptist Health South Florida
Phase
Phase 1
Overall status
Withdrawn
Start date
July 31, 2023
Completion date
July 31, 2028
Enrollment
0 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced squamous cell carcinoma, cutaneous squamous cell carcinoma, squamous cell carcinoma